SCHEMBL16892005

SCHEMBL16892005

CC(C)(C)OC(=O)N1C[C@H]2OCCN(C(=O)OCc3ccccc3)[C@H]2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
PREP P48147 1/20 0.45
PARP1 P09874 1/20 0.43
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
GAA P10253 1/20 0.41
THRB P10828 1/20 0.41
CCR5 P51681 1/20 0.41
NAMPT P43490 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
KLK7 P49862 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23556140 1.00 PDK1 (0.46) PDK1PDK2PDK3PDK4MEN1
SCHEMBL30007631 1.00 PDK1 (0.46) PDK1PDK2PDK3PDK4MEN1
SCHEMBL30007538 1.00 PDK1 (0.46) PDK1PDK2PDK3PDK4MEN1
SCHEMBL30161838 1.00 PDK1 (0.46) PDK1PDK2PDK3PDK4MEN1
SCHEMBL31200624 0.90 SMN1; SMN2 (0.49) PDK1PDK2PDK3PDK4MEN1
SCHEMBL31200555 0.88 SMN1; SMN2 (0.47) PDK1PDK2PDK3PDK4MEN1
SCHEMBL15816909 0.88 SMN1; SMN2 (0.47) PDK1PDK2PDK3PDK4MEN1
SCHEMBL15816908 0.88 SMN1; SMN2 (0.47) PDK1PDK2PDK3PDK4MEN1
SCHEMBL29725261 0.87 MEN1 (0.48) PDK1PDK2PDK3PDK4MEN1
SCHEMBL17693038 0.87 PARP1 (0.49) PDK1PDK2PDK3PDK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002408-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2023-01-05 US disclosed
CN-114867717-A Heteroaryl dihydropyrimidine derivatives and methods for treating hepatitis b infection 詹森药业有限公司 2022-08-05 CN disclosed
US-9949976-B2 Kinase inhibitor and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2018-04-24 US disclosed
US-20180000819-A1 KINASE INHIBITOR AND USE THEREOF Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2018-01-04 US disclosed
US-9796701-B2 Kinase inhibitor and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2017-10-24 US disclosed
US-9796701-B2 Kinase inhibitor and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2017-10-24 US disclosed
US-20160332989-A1 Kinase Inhibitor And Use Thereof Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2016-11-17 US disclosed
US-20160332989-A1 Kinase Inhibitor And Use Thereof Xuanzhu Biopharmaceutical Co., Ltd. (CN) 2016-11-17 US disclosed
WO-2015101293-A1 KINASE INHIBITOR AND USE THEREOF 山东轩竹医药科技有限公司 2015-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160332989-A1 Kinase Inhibitor And Use Thereof CDK4, CDK6, CDK3 PDK1 164/4885PDK2 463/4885PDK3 507/4885
US-20180000819-A1 KINASE INHIBITOR AND USE THEREOF CDK4, CDK6, CDK3 PDK1 164/4885PDK2 463/4885PDK3 507/4885
US-20230002408-A1 HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS HAVCR2, HCCS, PYGL PDK1 1028/4885PDK2 1110/4885PDK3 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.